Vigil Neuroscience

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Vigil Neuroscience headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $8.6B in funding across 48 round(s). With a team of 51-100 employees, Vigil Neuroscience is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Vigil Neuroscience, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.